The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.
This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
56
LIVACT contains 13.0 g of free amino acids
Kochi Medical School
Nankoku, Kochi, Japan
Postoperative tumor recurrence rate
Time frame: 5 years follow up
nutritional status
The secondary endpoint was a comparison of measurements of body weight, arm muscle circumference (AMC) between patient groups.
Time frame: 5 years follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.